Policy incentives are accelerating the domestic substitution, with Huada Zhizao (stock code: 688114) holding a market share of up to 63.8%, leading in the domestic sales of installed capacity.

According to the Wise Finance APP, on the evening of April 29th, Huada Zhizao (688114) released its 2024 annual report and 2025 first quarter report. The annual report shows that the company achieved a total operating income of 3.013 billion yuan for the year, an increase of 3.48% year-on-year. The revenue from the core gene sequencer business reached 2.348 billion yuan, an increase of 2.47% year-on-year, with related revenues from gene sequencer business in China reaching 1.607 billion yuan, an increase of 11.37% year-on-year, and over 1000 gene sequencers were newly sold in China. At the same time, the company's first quarter report further released a signal of reduced losses, with a nearly 34% decrease in net profit losses year-on-year, demonstrating business resilience against the backdrop of intensified global industrial chain competition. The company's refined management in the first quarter has been effective, with total sales, management, and research expenses decreasing by 19% year-on-year, and cost control measures showing significant results.